Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation

NCT03931642 is registered in ClinicalTrials.gov with French Innovative Leukemia Organisation as lead sponsor.

NCT NCT03931642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03931642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation
Lead sponsor
French Innovative Leukemia Organisation
Phase
Phase 2
Overall status
Completed
Start date
July 5, 2019
Completion date
October 21, 2022
Enrollment
41 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

richter syndrome